P74.02 Treatment Patterns of EGFR mt+ NSCLC IV pts: Real World Data of the NOWEL Network

The percentage of pts switching from 1st gen TKI in line to 3rd 2nd seems be low with 30% and it is questionable whether these data represent real world treatments. Therefore, we investigated the treatment pattern especially attrition rate between therapy EGFR mt+ pts. 965/1536 (63%) non-squamous NSCLC IV were tested for mt+. 148/965 (15%) an identified. To calculate PFS OS used Kaplan Meier log rang test p-values. Baseline characteristics 148 pts: median age 65 yrs; 64% female (n=95/148); never/light smoker (n=94/148). 135/148 (91%) carried either del19 (n=81) or L858R (n=55). 144/148 treated on (after chemotherapy). 14/144 are still line, 9 lost follow-up 3 died while line. We identified 118/144 candidates (because progression TKI) only 84/118 (70%) received a therapy. (36/118) did not receive because bad PS (n=26), refusal (n=2), fast (n=6) death (n=2). After accessibility 72 51/71 (71%) mOS receiving after access was 35 mo vs. 10 without (p<0.000). 32/51 T790M 20/32 (62%) T790M+. Highest one center 22/28 (79%). 16/20 (80%) T790M+ (n=31) 51 25 (p<0.002). A significant number do reach even broad TKI. Reasons most cases deterioration PS, no testing minority cases. These important interpretation FLAURA study as they reflect algorithms dedicated German lung cancer centers.